Serrano Oscar K, Tannebaum Jonathan E, Cumella Lindsay, Choi Jenny, Vemulapalli Pratibha, Scott Melvin W, Camacho Diego R
Montefiore Institute for Minimally Invasive Surgery, Montefiore Medical Center, Bronx, NY, USA.
Department of Surgery, Albert Einstein College of Medicine, 3400 Bainbridge Avenue, MAP 4., Bronx, NY, 104647, USA.
Surg Endosc. 2016 Jun;30(6):2505-11. doi: 10.1007/s00464-015-4509-y. Epub 2015 Aug 25.
Bariatric surgery has been established as the most effective long-term treatment for morbid obesity.
We performed a retrospective review of SSO patients treated at our institute between 2008 and 2013 who underwent a laparoscopic gastric bypass (LGBP) or sleeve gastrectomy (LSG). The primary end point for this study was excess weight loss (EWL) at 1, 3, 6, and 12 months. Secondary end points included procedure length (PL), length of stay (LOS), diabetes management and postoperative complications.
We identified 135 SSO patients who underwent bariatric surgery (93 LGBP, 42 LSG) at our institute from 2008 to 2013 with a median follow-up of 49 months. The incidence of EWL > 30 % for patients in the LGBP group was 3.9, 29.0, 72.2 and 94.6 % at 1, 3, 6 and 12 months, respectively, while the incidence of EWL > 30 % in patients in the LSG group was 4.2, 25.0, 59.1 and 100 % at 1, 3, 6 and 12 months, respectively. PL was 124 ± 49 min for the LGBP group and 98 + 51 min for the LSG group (p < 0.005). LOS was on average 3.0 days (range 1-21) for the LGBP group and 3.4 days (range 1-13) for the LSG group (p = 0.41). Patients experienced a decrease in their hemoglobin A1C level by 10 % for the LGBP group and 9 % for the LSG group at 1 year (p = 0.89). Postoperative complications were seen in 15.1 % of LGBP patients and 4.8 % of LSG patients.
Bariatric surgery is feasible in the SSO patients with comparable EWL outcomes and postoperative complications to historical non-SSO patients.
减重手术已被确立为治疗病态肥胖最有效的长期治疗方法。
我们对2008年至2013年在我院接受治疗的超级病态肥胖(SSO)患者进行了一项回顾性研究,这些患者接受了腹腔镜胃旁路术(LGBP)或袖状胃切除术(LSG)。本研究的主要终点是1、3、6和12个月时的超重减轻(EWL)。次要终点包括手术时间(PL)、住院时间(LOS)、糖尿病管理和术后并发症。
我们确定了2008年至2013年在我院接受减重手术的135例SSO患者(93例行LGBP,42例行LSG),中位随访时间为49个月。LGBP组患者在1、3、6和12个月时EWL>30%的发生率分别为3.9%、29.0%、72.2%和94.6%,而LSG组患者在1、3、6和12个月时EWL>30%的发生率分别为4.2%、25.0%、59.1%和100%。LGBP组的PL为124±49分钟,LSG组为98 + 51分钟(p<0.005)。LGBP组的LOS平均为3.0天(范围1 - 21天),LSG组为3.4天(范围1 - 13天)(p = 0.41)。1年后,LGBP组患者的糖化血红蛋白水平下降了10%,LSG组下降了9%(p = 0.89)。LGBP患者术后并发症发生率为15.1%,LSG患者为4.8%。
减重手术在SSO患者中是可行的,其EWL结果和术后并发症与既往非SSO患者相当。